Experienced pharmaceutical physician joins Boyds as Medical Director
Drug development consultancy Boyds has appointed Kate Owen as Medical Director in its Clinical and Medical Affairs team.
With more than 25 years’ experience as a pharmaceutical physician specialising in early development oncology, haemato-oncology, clinical pharmacology and ATMPs, Kate began her career training as an anaesthetist before working for a CRO. She then spent 16 years at AstraZeneca where she worked as Medicine and Science Director. In 2016, Kate became an independent consultant working with companies around the globe across small molecules, biologics, medical devices and cell therapy. Most recently, she held the post of Executive Medical Director at tranScrip.
Kate holds specialist registration in Pharmaceutical Medicine and is a Fellow of the Faculty of Pharmaceutical Medicine. She has also served on the board of examiners for the Faculty’s DipPharmMed exam, and continues to lecture on its respective revision course, plus other international programmes. She completed a MSc in ATMPs at the University of Manchester in 2021.
Based in Crewe, Kate will provide clinical and medical expertise to clinical development programmes, clinical trials, regulatory strategy, and medical affairs for Boyds’ global client base.
Speaking about her appointment, Kate said: “Boyds supports an impressive range of projects at every stage of development, led by a highly experienced team working from early translational medicine through to phase four studies. The company’s strong focus on cell and gene therapy, as well as other innovative Investigational Medicinal Products (IMPs), aligns perfectly with my interests following my MSc in ATMPs. I am looking forward to collaborating with such a knowledgeable team and supporting clients in navigating international markets and develop safe, effective, and compliant healthcare solutions.”
Professor Alan Boyd MBE, founder and CEO of Boyds, commented: “We are delighted to welcome Kate as Medical Director at Boyds. Alongside her specialist expertise in oncology, haemato-oncology and ATMPs, she brings an exceptional breadth of experience spanning translational medicine, first-in-human studies, clinical trial design, clinical development, clinical pharmacology, and medical monitoring. This combination of deep scientific knowledge and industry insight makes her a powerful addition to our team and a great asset to our clients and their projects.”
For more information, visit www.boydconsultants.com.
